The Pharma Data

DECEMBER 14, 2020

Preclinical research suggests that this antibody against the target can potentially address the existing pandemic, as well as escape mutants. . It has also shown that it has strong binding affinity to both SARS-CoV-2 and a second coronavirus in vitro. before expanding it into Europe.

Antibody 52

Antibody Licensing Licensing In-Vitro 52

The Pharma Data

DECEMBER 22, 2020

In vitro studies have provided compelling evidence supporting the view that Tmod-based cell therapy can distinguish tumor cells from normal cells, across multiple tumor targets,” said Dr. Perlmutter, President, Merck Research Laboratories. “We A2 will also receive from Merck an equity investment and reimbursement of certain expenses.

Development 52

Development Engineer Manufacturing In-Vitro 52

The Pharma Data

JANUARY 4, 2021

ViGeneron’s recognized expertise in retinal gene therapy together with Biogen’s leading research, drug development and commercialization experience is a powerful combination that we believe will allow us to deliver more novel gene therapies to patients in need.”. The companies will work together on the in vivo proof of concept (POC).

Gene Therapy 52

Gene Therapy Gene Development In-Vivo 52

XTalks

JUNE 12, 2023

These powerhouse organizations have not only distinguished themselves through their cutting-edge devices and technologies but also via their robust research and development (R&D) capabilities, unwavering commitment to quality and extensive global reach. 1) Medtronic 2022 Revenue: Medtronic reported an annual revenue of $31.69

FDA Approval 98

FDA Approval Production Sales In-Vitro 98

XTalks

JUNE 30, 2023

Sartorius is a globally recognized player in the diagnostics industry, providing a variety of solutions for in vitro diagnostics kit (IVD) manufacturers. In this Xtalks Spotlight feature, Xtalks spoke with two diagnostics experts from Sartoris: Wiktoria Banczyk, Strategy Analyst LPS, and Marvin (Ming) Xu, Manager of OEM DM Sales Asia.

In-Vitro 52

In-Vitro Manufacturing Production Antibody 52

XTalks

NOVEMBER 15, 2023

Valneva recently reported that it has been experiencing an increase in sales of its other vaccines due to the “recovery of the travel industry.” It appears the company has already done so as its quarterly earnings report included $96 million and $117 million of additional revenue from the sale of the PRV in its 2023 revenue guidance.

FDA Approval 59

FDA Approval Vaccine Vaccination In-Vitro 59

Delveinsight

JANUARY 12, 2021

Medivir is also eligible to receive milestone payments up to a total of approximately USD 350 million, plus tiered royalties up to mid-teens on net sales upon the commercial approval of the drug. Further, Birinapant also complements the anti-tumor activity of the immune system.

Licensing 52

Licensing Licensing Antibody Gene Therapy 52

The Pharma Data

MAY 3, 2021

Included were articles on the mid-career transition from research scientist to regulatory professional, continuous professional development and the value of graduate-level qualifications, and findings from two surveys on different aspects of the profession. Continuous professional development. Who is the average regulatory professional?

Development 52

Development Contamination In-Vitro Production 52

The Pharma Data

SEPTEMBER 1, 2020

Antigen test reliably and quickly triages people suspected of SARS-CoV-2, with results ready in 15 minutes, allowing informed treatment decisions. Antigen test accurately screens individuals with known exposure to infected SARS-CoV-2 patients, providing fast answers regarding their infection status. Food and Drug Administration (FDA).

In-Vitro 52

In-Vitro Antibody Medicine Clinical Trials 52

The Pharma Data

DECEMBER 2, 2020

The issuance and sale of the notes are scheduled to settle on December 7, 2020, subject to customary closing conditions. (NASDAQ: PROG) today announced the pricing of its offering of $75.0 million principal amount of notes. The notes will mature on December 1, 2025, unless earlier repurchased, redeemed or converted.

Sales 40

Sales In-Vitro Containment Development 40

The Pharma Data

SEPTEMBER 17, 2020

The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus. The test targets antibodies against the spike protein. This is the focus of vaccines in development and convalescent plasma therapy. Food and Drug Administration (FDA).

Antibody 52

Antibody Vaccine Vaccination In-Vitro 52

The Pharma Data

AUGUST 18, 2020

If it proves safe and effective in clinical trials and regulatory approvals are granted, Regeneron will distribute and record sales for REGN-COV2 in the U.S. Regeneron has progressed the REGN-COV2 research and development program at record speed and worked tirelessly to maximize our in-house manufacturing capacity,” said Leonard S.

Antibody 52

Antibody Clinical Trials Clinical Trials Manufacturing 52

The Pharma Data

DECEMBER 2, 2020

Progenity expects to use the net proceeds from the offering to support its operations, to invest in its molecular testing research and development program, to invest in research and development with respect to its precision medicine platform and for working capital and general corporate purposes. SAN DIEGO, Dec. About Progenity.

In-Vitro 40

In-Vitro Sales Containment Development 40

The Pharma Data

JANUARY 13, 2021

Receiving Fast Track designation is an important acknowledgment of the results of our COVID-19 laboratory research,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. Brilacidin antiviral research to date has been limited to laboratory-based experiments.

Clinical Trials 52

Clinical Trials Clinical Trials Trials In-Vitro 52

The Pharma Data

DECEMBER 14, 2020

Using in-silico tools, and also generating further in-vitro data from both neuronal cell-plates, and neurospheres, LP-184 demonstrated permeability that was in line with TMZ and other therapies being used in GBM today, while also demonstrating nano-molar potency. Lantern’s A.I. ” About Lantern Pharma.

Drugs 52

Drugs Genomics Genome DNA 52

The Pharma Data

OCTOBER 22, 2020

Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics.

In-Vitro 40

In-Vitro Clinical Trials Clinical Trials Clinical Development 40

The Pharma Data

SEPTEMBER 10, 2020

Findings will be presented at MSVirtual2020, the 8 th Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Roche’s Chief Medical Officer and Head of Global Product Development. and more than 2.3

In-Vitro 52

In-Vitro Medicine FDA Approval Clinical Trials 52

The Pharma Data

JUNE 25, 2021

AstraZeneca today announced results from the STORM CHASER trial assessing the safety and efficacy of AZD7442, a long-acting antibody (LAAB) combination, for the prevention of symptomatic COVID-19 in participants recently exposed to the SARS-CoV-2 virus. The PROVENT trial will give us more clarity in this patient population.

Trials 52

Trials Antibody In-Vitro Medicine 52

The Pharma Data

SEPTEMBER 8, 2020

Overviews of clinical trials and scientific rationale will be presented at MSVirtual2020, the 8th Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) from 11-13 September 2020. “We

Clinical Trials 52

Clinical Trials Clinical Trials Trials Medicine 52

The Pharma Data

SEPTEMBER 3, 2020

As COVID-19 and influenza infections can hardly be differentiated based on symptoms, healthcare professionals can confidently provide the right diagnosis and best course of treatment for patients. Test for use on high-throughput cobas 6800/8800 Systems will continue to support high volume testing .

In-Vitro 40

In-Vitro Antibody Medicine Clinical Trials 40

The Pharma Data

AUGUST 6, 2020

Safety for the Tecentriq combination appeared to be consistent with the known safety profile of the individual medicines, and no new safety signals were identified. Roche’s Chief Medical Officer and Head of Global Product Development. This includes studies evaluating Tecentriq both alone and in combination with other medicines.

Medicine 52

Medicine In-Vitro Protein Antibody 52

The Pharma Data

SEPTEMBER 9, 2020

Neurologist and Professor, University of British Columbia, and Research Chair of the MS Society of Canada. ENSPRYNG lowered relapse severity in double-blind periods of SAkura Phase III studies. Pooled data from SAkura open-label extension (OLE) studies support continued effect of ENSPRYNG reducing risk of relapse in the longer term.

Antibody 52

Antibody Medicine In-Vitro HR 52

The Pharma Data

AUGUST 22, 2021

Preliminary ‘in vitro’ findings from investigators at Oxford University and Columbia University demonstrate that AZD7442 neutralises recent emergent SARS-CoV-2 viral variants, including the Delta variant.(1-6). In the placebo arm, there were three cases of severe COVID-19, which included two deaths. About PROVENT.

Trials 52

Trials Antibody Vaccine Vaccination 52

The Pharma Data

AUGUST 16, 2020

“Today’s FDA approval of ENSPRYNG, the first subcutaneous NMOSD treatment using novel recycling antibody technology, builds upon the work we’ve done in multiple sclerosis with OCREVUS to develop first-in-class medicines and further the scientific understanding of neuroimmunological diseases,” said Levi Garraway, M.D., with placebo.

FDA Approval 52

FDA Approval Antibody Clinical Trials Clinical Trials 52

The Pharma Data

SEPTEMBER 2, 2020

Roche is also deeply committed to addressing barriers to clinical trial participation and advancing inclusive research. Initiation of Phase IIIb OCREVUS higher dose clinical trial programme and Phase IV study evaluating OCREVUS in minority populations. Roche’s Chief Medical Officer and Head of Global Product Development.

Clinical Trials 52

Clinical Trials Clinical Trials Antibody Medicine 52

The Pharma Data

MAY 4, 2021

Following the completion of the spin-off of the Upjohn Business (4) in the fourth quarter of 2020, Pfizer now operates as a focused innovative biopharmaceutical company engaged in the discovery, development, manufacturing, marketing, sales and distribution of biopharmaceutical products worldwide. per share amounts). Reported Diluted EPS (1).

Vaccine 40

Vaccine Vaccination Production Sales 40

The Pharma Data

JULY 23, 2021

The antibody combination was granted a Special Approval Pathway under article 14-3 of the Pharmaceuticals and Medical Devices Act. “Ronapreve has been shown to improve survival in high-risk, non-hospitalised COVID-19 patients by reducing the risk of hospitalisation and death.

Antibody 52

Antibody Medicine Production In-Vitro 52

The Pharma Data

SEPTEMBER 19, 2020

Data from the Phase III IMpassion031 study demonstrated that Tecentriq in combination with chemotherapy improved pathological complete response for patients with early triple-negative breast cancer (TNBC), when compared to placebo plus chemotherapy. Roche’s Chief Medical Officer and Head of Global Product Development. from 41.1% (95% CI: 33.6–48.9)

HR 52

HR Medicine In-Vitro Development 52

The Pharma Data

JUNE 26, 2021

The RECOVERY Actemra/RoActemra study was led by researchers in the United Kingdom and included more than 4,000 hospitalised COVID-19 patients. The RECOVERY Actemra/RoActemra study was led by researchers in the United Kingdom and included more than 4,000 hospitalised COVID-19 patients. Actemra/RoActemra has not been approved by the U.S.

Clinical Trials 40

Clinical Trials Clinical Trials In-Vitro Antibody 40

The Pharma Data

MAY 18, 2021

If approved, ENSPRYNG will be the first and only treatment available to both adults and adolescents from 12 years of age with anti-aquaporin-4 antibody (AQP4-IgG) seropositive NMOSD in the EU. ENSPRYNG is the only subcutaneous treatment option for NMOSD that can be administered at home every four weeks.

Antibody 40

Antibody Medicine In-Vitro Development 40

The Pharma Data

APRIL 27, 2021

The advisory committee provides the FDA with independent opinions and recommendations from outside medical experts, though the recommendations are not binding. The FDA has not announced when it will make its final decision for Tecentriq in this indication. Roche’s Chief Medical Officer and Head of Global Product Development.

Medicine 40

Medicine In-Vitro Antibody Development 40

The Pharma Data

APRIL 23, 2021

Roche announces positive CHMP opinion for Venclyxto-based combinations in certain patients with acute myeloid leukaemia. Venclyxto combinations significantly improved complete response rates in people with newly diagnosed acute myeloid leukaemia in two key studies (VIALE-A and M14-358). The median OS was 14.7 months (95% CI: 11.9, months (95% CI: 7.4,

Medicine 40

Medicine In-Vitro Antibody Development 40

The Pharma Data

SEPTEMBER 16, 2020

New and updated data from across our broad cancer portfolio including phase III results in breast, lung and prostate cancers. New integrated analyses from our tumour agnostic Rozlytrek ® (entrectinib) clinical development programme. Join this event on Roche’s LinkedIn page here. Roche highlights featured at ESMO Virtual Congress 2020.

HR 52

HR Medicine Hormones Trials 52

The Pharma Data

FEBRUARY 25, 2021

Roche announces results from Evrysdi (risdiplam) study in infants with Type 1 spinal muscular atrophy (SMA) published in New England Journal of Medicine. The FDA approved Evrysdi in August 2020 as the first and only at home SMA treatment with proven efficacy in adults, children and infants 2 months and older.

Protein 52

Protein Medicine FDA Approval In-Vitro 52

The Pharma Data

SEPTEMBER 27, 2020

Exploratory efficacy data showed 88% of infants treated with Evrysdi were alive and did not require permanent ventilation at two years. 59% of infants were able to sit without support for at least 5 seconds. No new safety signals were identified. In August, the FDA approved Evrysdi for the treatment of SMA in adults and children 2 months and older.

Protein 52

Protein In-Vitro Medicine FDA Approval 52

Pharmaceutical Technology

FEBRUARY 28, 2023

Eucure Biopharma will receive up to $28.17m (¥196m) in potential sales milestone payment and tiered royalties on net sales. The bispecific antibody was found to conditionally activate the immune pathway in the tumour microenvironment in vitro and in vivo trials.

In-Vivo 130

In-Vivo Antibody In-Vitro Licensing 130

XTalks

SEPTEMBER 14, 2020

Tension is mounting as nations big and small jockey around industry to ensure they are first in line to access a vaccine, should one prove to be successful against COVID-19. By the end of August, the World Health Organization (WHO) counted 33 vaccine candidates in some stage of clinical trial evaluation. The price of that prize is incalculable.

Vaccine 92

Vaccine Vaccination Antibody Life Science 92